Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110012/S023

Vysis ALK Break Apart FISH Probe Kit

Abbott Molecular, Inc. · Decision date Feb 18, 2026

FDA DECISIONP110012/S023

What did the FDA decide?

FDA records P110012/S023 as a supplement to PMA P110012, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 18, 2026.

FDA approval order statement

implementation of a secondary packaging process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Feb 18, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P110012/S023
Regulatory pathway
PMA supplement
Product code
OWE
Decision code
OK30
Decision date
Feb 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Fluorescence In Situ Hybridization, Anaplastic Lymphoma Kinase, Gene Rearrangement.

Product code
OWE
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P110012/S022 · Related supplement

    Vysis ALK Break Apart FISH Probe Kit

  2. P110012/S023 received

    Application receipt date recorded by FDA.

  3. P110012/S023 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P110012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110012

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Molecular, Inc.PMA supplementAug 5, 2025FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Molecular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1300 E Touhy Ave., Des Plaines, IL, 60018

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records